E-LIB Suche - Ergebnisse für: Nilsson, Mary

1

Clinical Trial Drug Safety Assessment for Studies and Submi..:

Nilsson, Mary ; Crowe, Brenda ; Anglin, Greg...
Statistics in Biopharmaceutical Research. 12 (2020) 4 - p. 498-505 , 2020

Link: https://doi.org/10.1080/..

2

Clinical Trial Drug Safety Assessment With Interactive Visu..:

Wang, Wei ; Revis, Rebeka ; Nilsson, Mary.
Statistics in Biopharmaceutical Research. 13 (2020) 3 - p. 355-366 , 2020

Link: https://doi.org/10.1080/..

3

Adaptation of the robust method to large distributions of r..:

Beasley Jr., Charles M. ; Crowe, Brenda ; Nilsson, Mary...
Journal of Biopharmaceutical Statistics. 29 (2019) 3 - p. 516-528 , 2019

Link: https://doi.org/10.1080/..

4

Reference Limits for Outlier Analyses in Randomized Clinica..:

Beasley, Charles M. ; Crowe, Brenda ; Nilsson, Mary...
Therapeutic Innovation & Regulatory Science. 51 (2017) 6 - p. 683-737 , 2017

Link: https://doi.org/10.1177/..

5

Novel Role for Proteinase-activated Receptor 2 (PAR2) in Me..:

Cunningham, Margaret R. ; McIntosh, Kathryn A. ; Pediani, John D....
Journal of Biological Chemistry. 287 (2012) 20 - p. 16656-16669 , 2012

Link: https://doi.org/10.1074/..

6

Dual effect of the novel peptide antagonist K‐14585 on prot..:

Goh, Fui Goon ; Ng, Pei Yuen ; Nilsson, Mary..
British Journal of Pharmacology. 158 (2009) 7 - p. 1695-1704 , 2009

Link: https://doi.org/10.1111/..

7

G-protein-dependent and -independent pathways regulate prot..:

Goon Goh, Fui ; Sloss, Callum M. ; Cunningham, Margaret R....
Cellular Signalling. 20 (2008) 7 - p. 1267-1274 , 2008

Link: https://doi.org/10.1016/..

8

Safety of Subchronic Treatment with Fluoxetine for Major De..:

Nilsson, Mary ; Joliat, Melissa J. ; Miner, Cherri M...
Journal of Child and Adolescent Psychopharmacology. 14 (2004) 3 - p. 412-417 , 2004

Link: https://doi.org/10.1089/..

9

Identifying Potential Adverse Events Dose-Response Relation..:

Fu, Haoda ; Price, Karen L. ; Nilsson, Mary E..
Journal of Biopharmaceutical Statistics. 23 (2013) 1 - p. 26-42 , 2013

Link: https://doi.org/10.1080/..

10

No gender differences in placebo responses of patients with..:

Casper, Regina C ; Tollefson, Gary D ; Nilsson, Mary E
Biological Psychiatry. 49 (2001) 2 - p. 158-160 , 2001

Link: https://doi.org/10.1016/..

11

Defining Treatment-Emergent Adverse Events with the Medical..:

Nilsson, Mary E. ; Koke, Stephanie C.
Drug Information Journal. 35 (2001) 4 - p. 1289-1299 , 2001

Link: https://doi.org/10.1177/..

12

Fluoxetine versus sertraline and paroxetine in major depres..:

Fava, Maurizio ; Rosenbaum, Jerrold F ; Hoog, Sharon L...
Journal of Affective Disorders. 59 (2000) 2 - p. 119-126 , 2000

Link: https://doi.org/10.1016/..

13

Adverse events and treatment discontinuations in clinical t..:

Beasley Jr., Charles M. ; Koke, Stephanie C. ; Nilsson, Mary E..
Clinical Therapeutics. 22 (2000) 11 - p. 1319-1330 , 2000

Link: https://doi.org/10.1016/..

14

Clinical Trial Drug Safety Assessment for Studies and Submi..:

Nilsson, Mary ; Crowe, Brenda ; Anglin, Greg...
http://arxiv.org/abs/2006.05502. , 2020

Link: http://arxiv.org/abs/200..

15

Novel role for proteinase-activated receptor 2 (PAR2) in me..:

Cunningham, Margaret R ; McIntosh, Kathryn A ; Pediani, John D...
https://strathprints.strath.ac.uk/44379/1/Cunningham_J._Biol._Chem._2012.pdf. , 2012

Link: https://strathprints.str..